Literature DB >> 15306108

Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window.

Ignacio Moncada1, José Jara, David Subirá, Irene Castaño, Carlos Hernández.   

Abstract

OBJECTIVE: This open-label study investigated the efficacy of sildenafil citrate at 12 hours postdose among prior treatment responders. PATIENTS AND METHODS: Eight 100-mg doses of sildenafil were provided to 40 eligible patients with erectile dysfunction (ED), who were to record the results of each sexual attempt in a patient diary. Each patient was instructed to make a sexual attempt at 1 and 12 hours postdose on 4 occasions (part 1) and only at 12 hours postdose on 4 subsequent occasions (part 2).
RESULTS: Of 40 enrolled patients, 34 (85%) completed the study. In these evaluable patients, 97% and 74% of patients achieved erections that resulted in successful intercourse at 1 hour and 12 hours postdose, respectively. There was a nonsignificant reduction in the percentage of responders at 12 hours during part 1 versus part 2 of this study (71% versus 78%).
CONCLUSIONS: This study demonstrates that, in the majority of these patients with ED, sildenafil remains clinically active 12 hours after administration. Larger studies may be necessary to confirm and clarify the therapeutic window of sildenafil.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306108     DOI: 10.1016/j.eururo.2004.04.025

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  14 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.

Authors:  Victor Palit; Ian Eardley
Journal:  Nat Rev Urol       Date:  2010-11       Impact factor: 14.432

Review 3.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.

Authors:  Andrew McCullough
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

Review 5.  Udenafil for the treatment of erectile dysfunction.

Authors:  Min Chul Cho; Jae-Seung Paick
Journal:  Ther Clin Risk Manag       Date:  2014-05-14       Impact factor: 2.423

6.  The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Authors:  Ghazwan Butrous
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

Review 7.  Erectile Dysfunction: A Primer for in Office Management.

Authors:  Samir Sami; Noah Stern; Andrew Di Pierdomenico; Brandon Katz; Gerald Brock
Journal:  Med Sci (Basel)       Date:  2019-08-29

Review 8.  Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?

Authors:  Yoram Vardi
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 9.  Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Konstantinos Hatzimouratidis
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

10.  Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men.

Authors:  Luca Loprete; Chiara Leuratti; Valeria Frangione; Milko Radicioni
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.